A. Cisplatin has a 10%–15% response rate in most tumors B. Cisplatin in combination with gemcitabine exhibits synergy in pre-clinical models of triple-negative breast cancer C. PARP inhibitors show single-agent activity in BRCA 1/2 mutant ovarian cancer D. PARP inhibitors in combination with temozolomide exhibit activity in glioblastomas

A. They are only efficacious in tumors with germline BRCA mutations B. They are only efficacious in tumors with somatic (acquired) BRCA mutations C. They have demonstrated efficacy in the treatment tumors with germline and/or somatic (acquired) BRCA mutations

A. Olaparib B. Niraparib C. Rucaparib D. Olaparib, rucaparib, niraparib

A. Fatigue is unusual with PARP inhibitor therapy; dose reductions are not commonly recommended for severe fatigue. B. If a patient experiences nausea and/or vomiting, trial prophylactic antiemetics 30–60 minutes prior to PARP inhibitor dosing. C. If a patient experiences any level of bone marrow suppression on PARP inhibitor therapy, treatment should be permanently discontinued. D. Cardiovascular side effects, such as hypertension, are commonly seen with all PARP inhibitors.